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Abstract 
Background: Subjects with type 2 diabetes have high circulating levels of glucose. Glucagon-like 
peptide-1 (GLP-1) is an intestinal hormone that has a major role in glucose homeostasis.  Exenatide 
and liraglutide are both agonists at the GLP-1 receptor, and are effective at reducing circulating 
glucose levels (measured as HbA1c levels), but they have not been compared.  Objectives/Methods: 
This evaluation is of a clinical trial comparing liraglutide once a day with exenatide twice a day in 
subjects with type 2 diabetes.  Results: In the Liraglutide Effect and Action in Diabetes (LEAD)-6 trial, 
subcutaneous liraglutide 1.8 mg once a day was compared to exenatide 10 µg twice a day.  The 
primary efficacy outcome was change in HbA1c levels, and this was significantly greater with liraglutide 
(1.12%) than with exenatide (0.79%).  Liraglutide and exenatide had similar small abilities to reduce 
body weight, blood pressure and LDL-cholesterol.  Conclusions: Liraglutide was more effective than 
exenatide for overall glycaemic control in subjects with type 2 diabetes.  However, this is only true for 
the preparations and doses tested i.e. liraglutide 1.8 mg once weekly and exenatide 10 µg b.i.d., and 
may not apply when the comparison is undertaken with the new longer lasting preparation of 
exenatide once weekly. 
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1. Introduction 
Of the 17 million people in the US who have diabetes, 90% of them have type 2 diabetes.  Diabetics 
cannot manage glucose properly, and this leads to damage to the retina, kidney, and nerves, and 
increases the risk of cardiovascular disease and stroke. 
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that has a major role in glucose 
homeostasis.  For instance, GLP-1 stimulates insulin secretion but inhibits glucagon secretion, slows 
gastrointestinal motility, and increases satiety.  GLP-1 is rapidly degraded by dipeptidyl peptidase-4 
(DPP-4).  Exendin-4 is a 39-amino acid peptide, originally isolated from the venom of a lizard, which 
acts as an agonist at the GLP-1 receptor.   Exenatide is a synthetic form of exendin-4 that has 53% 
amino acid identity with GLP-1.  Liraglutide is an analog of human GLP-1 with only one amino acid 
substituted, and a C-16 palmitic-acid side chain added, to provide resistance to breakdown by DPP-4.   
As discussed briefly in Sections 2 and 3, clinical trials have demonstrated that both exenatide and 
liraglutide are effective at reducing circulating glucose levels (measured as HbA1c levels) but they have 
only recently been compared.  The comparator trial of exenatide b.i.d. and liraglutide, which shows 
that liraglutide may have some benefits over exenatide b.i.d. [1], is the trial considered in this 
evaluation.  
2. Exenatide twice a day 
The subcutaneous administration of exenatide b.i.d. alone has been shown to reduce HbA1c levels in 
subjects with type 2 diabetes [reviewed in 2].  Subsequently, exenatide b.i.d. s.c. has been shown to 
reduce HbA1c levels in subject with type 2 diabetes taking metformin alone, a sulfonylurea alone, or 
metformin and a sulfonylurea with few adverse effects [2].  Exenatide may also be as effective as 
insulin glargine in subjects with type 2 diabetes not adequately controlled with oral agents [2].   
In addition to reducing HbA1c levels in subject with type 2 diabetes taking metformin, exenatide 
reduces body weight, blood pressure, LDL-cholesterol, and triglycerides while increasing the levels of 
HDL-cholesterol [2].   The most common adverse effects with exenatide are nausea and upper 
respiratory tract infection, but these adverse effects diminish with ongoing treatment [2].   
3. Liraglutide Effect and Action in Diabetes (LEAD) 
The Phase III clinical development of liraglutide is being undertaken as the LEAD programme, and 5 
of these have been published in 2009.  In LEAD-1 SU, liraglutide was added to a sulfonylurea 
(glimepiride), and compared to placebo and a glitazone (rosiglitazone) over 26 weeks [3].  In the 
presence of glimepiride, liraglutide 1.2 or 1.8 mg s.c. was more potent than placebo or rosiglitazone at 
reducing the HbA1c levels in subject with type 2 diabetes [3].  Liraglutide had little effect on body 
weight, whereas rosiglitazone increased it [3].   
In LEAD-2, liraglutide was added to metformin, and compared to glimepiride over 26 weeks [4].  
Liraglutide had the same ability as glimepiride to reduce HbA1c levels, but caused a loss of body 
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weight whereas glimepiride increased body weight [4].  Liraglutide caused less hypoglycaemia than 
glimepiride [4]. In LEAD-3, liraglutide was compared to glimepiride as monotherapy over 52 weeks, 
and shown to reduce HbA1c levels to a greater extent than glimepiride (1.1% vs 0.8%) [5].  In LEAD-4, 
liraglutide was added to metformin and rosiglitazone, and compared to placebo, and shown to 
decrease HbA1c levels and body weight in subjects with type 2 diabetes [6].  In LEAD-5, liraglutide is 
being compared to insulin glargine in subjects inadequately controlled with metformin and glimepiride 
[7], and the results of this clinical trial have not been reported in the peer-reviewed press, to date. 
4. LEAD-6: Liraglutide vs exenatide 
 
4.1 Method and results 
LEAD-6 compared liraglutide with exenatide [1], and is the subject of this evaluation with the methods 
and results being combined in this section.  LEAD-6 enrolled subjects with type 2 diabetes with HbA1c 
levels of 7-11% and body mass index of ≤ 45 kg/m2, who were taking maximally tolerated doses of 
metformin, a sulfonylurea, or both.  The 464 enrolled subjects had a mean age of ~57 years old, were 
predominantly white, had a BMI of 33 kg/m2, and baseline HbA1c levels of ~8.15%.  Most of the 
enrolled were taking both metformin and a sulfonylurea (63%), whereas metformin alone was taken 
by 27%, and a sulfonylurea by 10%. 
LEAD-6 was a 26-week, open-label, parallel-group study, which randomised subjects, via dose-
escalation, to subcutaneous liraglutide 1.8 mg once a day or exenatide 10 µg twice a day.  The 
primary efficacy outcome was change in HbA1c levels, and this was significantly greater with liraglutide 
(1.12%) than with exenatide (0.79%).   
The secondary efficacy outcomes were changes in plasma glucose levels, which were measured and 
recorded by the subjects with type 2 diabetes.  Liraglutide reduced fasting levels of plasma glucose to 
a greater extent (1.6 mmol/L) than did exenatide (0.6 mmol/L), but exenatide reduced the increase in 
plasma glucose after meals to a greater extent (e.g. 1.33 mmol/L at breakfast) than liraglutide (1.86 
mmol/L).  Body weight was reduced to a similar extent by liraglutide (3.24 kg) and exenatide (2.87 
kg). 
Pancreatic β-cell function was improved to a greater extent by liraglutide than exenatide.  Thus, 
fasting insulin levels rose with liraglutide but not with exenatide, and the homoeostasis model 
assessment of β-cell function (HOMA-B) increased to a greater extent with liraglutide than exenatide.  
Triglycerides and free fatty acids were also reduced to a greater extent with liraglutide than exenatide.  
However, liraglutide and exenatide had similar abilities to reduce blood pressure (liraglutide, 2.5/1.1 
mmHg; 2.0/1.9 mmHg) and LDL-cholesterol.  Liraglutide increased heart rate to a greater extent (3.28 
beats/min) than exenatide (0.69 beats/min).  Overall treatment satisfaction was assessed using the 
Diabetes Treatment Satisfaction Questionnaire, and liraglutide rated slightly higher than exenatide. 
There were more serious adverse effects with liraglutide (5.1%) than with exenatide (2.6%).  Adverse 
events were similar in both groups with a high incidence of gastrointestinal disorders (liraglutide, 46%; 
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exenatide, 43%) especially nausea, and of infections/infestations (liraglutide, 33%; exenatide 37%).  
The incidence of nausea decreased, with time, to a greater extent with liraglutide than exenatide.  
Major hypoglycaemia was observed in 2 subjects taking exenatide and a sulfonylurea, but in none 
taking liraglutide.  Minor hypoglycaemia was lower with liraglutide (26%) than with exenatide (34%), 
with more occurring in combination with a sulfonylurea than metformin.   
4.2 Discussion  
The authors conclude that liraglutide once a day was more effective than exenatide twice a day for 
overall glycaemic control [1]. 
5. Expert opinion 
 
5.1 Are the reductions in HbA1c levels consistent with other trials? 
The best evidence comparing drugs is from a comparator trial, and in the comparator trial liraglutide 
lowered HbA1c levels to a greater extent (1.12%) than exenatide b.i.d (0.79%) [1].  However, it is 
unusual that the reduction in HbA1c levels reported for exenatide b.i.d., in the study comparing it to 
liraglutide, in the presence of metformin, a sulfonylurea, or both, is lower than previously reported.  
Thus, previously, in the presence of metformin, exenatide b.i.d. lowered HbA1c levels by 1.1%, in the 
presence of a sulfonylurea by 0.86%, and in the presence of metformin, a sulfonylurea or both by 
1.0% [2].  Also, with similar baseline HbA1c levels, recently exenatide b.i.d. was compared to exenatide 
once weekly, and exenatide b.i.d. was shown to reduce HbA1c levels by 1.5% [8].  No explanation is 
offered by the authors on the difference.  I do not have an explanation for this either, but it should be 
noted that the result is not in agreement with previous findings using exenatide b.i.d. 
In contrast, the reduction in HbA1c levels in the study comparing liraglutide to exenatide with liraglutide 
is similar (1.12%) to that previously reported for liraglutide.  Thus, liraglutide reduced HbA1c levels by 
1.24% as monotherapy [5], by 1.1% in subjects also treated with metformin [4], and by 1.1% in 
subjects treated with a sulfonylurea [3].  
5.2 Exenatide once a week 
There is evidence that exenatide once a week is better than exenatide b.i.d., and some evidence that 
it may be better than liraglutide, and thus, exenatide once a week and liraglutide should undergo a 
comparator study.  In 2008, it was convincingly shown that a once-weekly slow release formulation of 
exenatide 2 mg s.c. was more effective than exenatide 10 µg b.i.d. s.c. in reducing HbA1c levels in 
subject with type 2 diabetes [8].  In this study, drug-naïve subjects or subjects on one or more diabetic 
medication were randomised to the different forms of exenatide for 30 weeks [8].  HbA1c levels were 
reduced to a greater extent in the once weekly group (from 8.3 to 6.4%) than in the twice daily group 
(8.3 to 6.8%) [8].  
If the data for liraglutide (from the comparison with exenatide b.i.d.), is compared to that of exenatide 
once weekly, it suggests that exenatide once weekly may lower HbA1c levels to a greater extent than 
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liraglutide.  Thus, exenatide once weekly reduced HbA1c levels by 1.5% [8] whereas liraglutide lowered 
HbA1c levels by 1.12% [1].  
5.3 Albiglutide 
Albiglutide is a long-acting GLP-1 receptor agonist that can be used weekly, biweekly or monthly to 
reduce lower HbA1c levels in subjects with type 2 diabetes [9].  Recently, albiglutide has been shown 
to be more potent than exenatide b.i.d. at reducing HbA1c levels [9].  Thus, comparator trials between 
albiglutide and liraglutide, and between albiglutide and exenatide once weekly, are indicated. 
5.4 Pancreatitis 
Pancreatitis has been reported in subjects taking both exenatide and liraglutide, and this may be a 
feature of GLP 1 receptor agonists [10].  Consequently, it has been recommended that exenatide and 
liraglutide not be used in subjects at risk of pancreatitis (e.g. with alcoholism, cholecystolithiasis, or 
hypertriglyceridaemia) [10].   
5.5 Clinical endpoints 
To date, exenatide and liraglutide have only been studied on markers of clinical disease e.g. HbA1c 
levels.  Thus, long-term studies of the effects on exenatide and liraglutide on clinical outcomes e.g. 
incidence of cardiovascular disease, need to be undertaken.   
5.6 Conclusions 
Liraglutide was more effective than exenatide for overall glycaemic control in subjects with type 2 
diabetes.  However, this is only true for the preparations and doses test i.e. liraglutide 1.8 mg once 
weekly and exenatide 10 µg b.i.d., and may not apply when the comparison is undertaken with the 
new longer lasting preparation of exenatide once weekly. 
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